Document Detail

Eosinophilic myeloid neoplasms.
MedLine Citation:
PMID:  23385615     Owner:  NLM     Status:  In-Data-Review    
PURPOSE OF REVIEW: In 2012, idiopathic hypereosinophilic syndrome (HES) is still the prevalent diagnosis in patients with persistent eosinophilia, in which a primary or secondary cause of eosinophilia has not been identified. HES is considered a provisional diagnosis until a primary or secondary cause of hypereosinophilia is established. The discovery of imatinib-sensitive fusion proteins in a subset of patients with hypereosinophilia has changed the way we approach the diagnosis and treatment of eosinophilic myeloid neoplasms [eosinophilic myeloproliferative neoplasms (MPNs)]. Despite the recent diagnostic developments, diagnosis of hypereosinophilic MPN is only made in 10-20% of patients with persistent primary hypereosinophilia.
RECENT FINDINGS: In 2008 the World Health Organization (WHO) established a semi-molecular classification of hypereosinophilic MPNs. The discovery of PDGFRA, PDGFRB, FGFR1, JAK-2, and FLT3 fusion proteins in patients with eosinophilic MPNs provide opportunities for targeted therapy. Patients with hypereosinophilic MPNs associated with PDGFRA and PDGFRB fusion genes are responsive to imatinib.
SUMMARY: Ongoing research continues to expand our understanding of the pathophysiology of persistent primary hypereosinophilia and clarify the boundaries between some of these disorders. A key challenge is to identify new targets for therapy and limit the number of patients who are classified as having HES.
Pierre Noel; Ruben A Mesa
Related Documents :
12889665 - Classical homocystinuria: vascular risk and its prevention.
23535815 - Acute pulmonary emboli in a patient on long-term dabigatran therapy (april).
22115335 - Factors associated with the mediastinal spread of cervical necrotizing fasciitis.
22400085 - Evaluation of adherence to oral antiviral hepatitis b treatment using structured questi...
3425485 - Spinal cord meningiomas in the elderly.
1312815 - White blood cell activation in raynaud's phenomenon of systemic sclerosis and vibration...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in hematology     Volume:  20     ISSN:  1531-7048     ISO Abbreviation:  Curr. Opin. Hematol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9430802     Medline TA:  Curr Opin Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  157-62     Citation Subset:  IM    
Division of Hematology Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
Next Document:  Beyond correlates: a review of risk and protective factors for adolescent dating violence perpetrati...